Cerebrovascular Disease - Nephrology Lectures 2025

Visual reference

Severe BP and Neurologic Disease: Identify Organ Injury visual summary. Open for the full image and text version. — Severe BP and Neurologic Disease: Identify Organ Injury: full graphic and text version

Browse the visual reference library · Download lesson Markdown

🎯 Precision Management Revolution

The 2025 guidelines provide refined, evidence-based protocols for acute cerebrovascular management, distinguishing between intracerebral hemorrhage subtypes and post-endovascular therapy scenarios. These nuanced approaches optimize outcomes while minimizing harm.

🩸 Acute Intracerebral Hemorrhage Management

⏰ Time-Critical Intervention Window

Initiate BP control within 2 hours of symptom onset when hematoma expansion risk peaks. This narrow window is crucial for preventing secondary injury.

Class 2a
Selected mild-to-moderate ICH with presenting SBP 150–220: target 140 mmHg, maintain 130–150 (AHA/ASA 2022 guideline)
Duration: 7 days post-hemorrhage

💎 Critical Evidence Integration

The refined Class 2a recommendation reflects nuanced interpretation of INTERACT-2 (showing benefit) and ATACH-2 (showing potential harm from overly aggressive reduction). The target avoids SBP <130 mmHg to prevent cerebral hypoperfusion in the setting of impaired autoregulation.

📋 Stepwise Management Protocol

0-2 hrs

Initial Assessment & Stabilization

Immediate neuroimaging (CT), coagulation studies, baseline neurological assessment. Establish IV access, initiate continuous BP monitoring.

2-6 hrs

Intensive BP Management

Target SBP 140 mmHg using continuous infusion agents. Nicardipine (preferred), labetalol, or esmolol for precise titration.

6-24 hrs

Maintenance & Monitoring

Continue SBP 130-139 mmHg range. Serial neurological assessments, repeat imaging if deterioration. Monitor for cerebral edema.

1-7 days

Sustained Control

Transition to oral agents using the stroke team’s individualized target. Begin rehabilitation planning, address secondary prevention.

🎯 Preferred IV Agents

Nicardipine: 5-15 mg/hr infusion
Labetalol: 10-20 mg boluses or 0.5-2 mg/min
Esmolol: 25-300 mcg/kg/min (if no contraindications)

⚠️ Avoid These Agents

Sublingual nifedipine: Unpredictable, excessive reduction
IV hydralazine: Uncontrolled, precipitous drops
IV metoprolol: Potential CNS depression

Post-Endovascular Therapy: Trial Evidence

ENCHANTED2/MT: very intensive lowering caused harm

After successful thrombectomy, ENCHANTED2/MT compared an SBP target <120 mmHg with 140–180 mmHg for 72 hours in patients with persistently elevated BP. The <120 strategy worsened functional outcomes. Yang et al., Lancet 2022.

Avoid the very intensive <120 mmHg strategy tested in ENCHANTED2/MT.
The trial does not establish that every SBP below 140 is harmful.

Apply the result in context

Individualize post-thrombectomy BP management with the stroke team and current local stroke protocol, accounting for reperfusion, neurologic status, hemorrhage and comorbid illness. Do not use the trial comparator as a reason to raise every lower BP to 140 mmHg. Antithrombotic decisions require a separate stroke-specific indication and bleeding assessment.

🧊 Acute Ischemic Stroke (Non-Endovascular)

Class 1
Permissive hypertension: Allow SBP <220 mmHg, DBP <120 mmHg
Avoid aggressive reduction in acute phase

🎯 Management by Clinical Scenario

💉 tPA Candidates

Reduce SBP to <185 mmHg before tPA
Maintain <180/105 mmHg for 24 hours post-tPA
Use nicardipine or labetalol
Monitor for hemorrhagic conversion

🚫 Non-tPA Patients

Permissive hypertension: SBP <220 mmHg
Avoid routine BP reduction
Preserve penumbral perfusion
Begin reduction after 24-48 hours

🫀 Cardiac Complications

Acute MI: standard ACS protocols
Heart failure: careful diuresis
Arrhythmias: rate/rhythm control
Aortic dissection: emergency surgery

🧠 Neurological Deterioration

Cerebral edema: osmotic therapy
Hemorrhagic conversion: BP control
Malignant MCA syndrome: consider surgery
Seizures: antiepileptic therapy

🧠 Cognitive Preservation & Dementia Prevention

📈 SPRINT-MIND Evidence Integration

🎯 Intensive BP Control

19% reduction in mild cognitive impairment with SBP <120 mmHg vs <140 mmHg

📊 Composite Cognitive Outcomes

15% reduction in combined MCI and probable dementia outcomes

🧪 White Matter Protection

Reduced small vessel disease progression and white matter hyperintensity burden

Class 1 Upgrade
Target SBP <130 mmHg for cognitive preservation
Particularly important in midlife hypertension

🔬 Mechanistic Understanding

Midlife hypertension particularly predicts late-life cognitive decline through small vessel disease, blood-brain barrier disruption, and chronic cerebral hypoperfusion. The Class 1 upgrade supports aggressive treatment in younger patients for brain health preservation beyond cardiovascular protection.

📋 Cognitive Protection Protocol

👥 Target Populations

Adults 50+ years with CV risk factors
No history of diabetes or stroke
Absence of orthostatic hypotension
Life expectancy >3 years

🎯 Implementation Strategy

Gradual SBP reduction to <130 mmHg
Monitor cognitive function annually
Screen for depression and anxiety
Encourage cognitive stimulation

⚖️ Risk-Benefit Assessment

Balance cognitive benefits vs fall risk
Avoid excessive reduction (<110 mmHg)
Consider frailty status
Regular medication tolerance review

🧪 Adjunctive Measures

Lipid management (statins)
Diabetes prevention/control
Physical exercise programs
Social engagement promotion

💊 Cerebrovascular-Specific Medication Considerations

Clinical Scenario	Preferred Agents	Target BP	Monitoring	Contraindications
Acute ICH	Nicardipine, labetalol, esmolol	Selected mild-to-moderate ICH: target 140; maintain 130–150	Continuous BP, neuro checks q1h	Sublingual nifedipine, hydralazine
Post-Endovascular	Individualized stroke-team protocol	ENCHANTED2/MT comparator: 140–180; individual clinical target varies	Neuro status, vessel patency	Very intensive target <120 tested in ENCHANTED2/MT
tPA Eligible	Nicardipine, labetalol	SBP <185 pre-tPA, <180 post	BP q15min × 2hr, then q30min	Beta-blockers (relative)
Chronic Prevention	ACE inhibitors, thiazides, CCBs	SBP <130 mmHg	Cognitive assessment annually	Excessive reduction <110 mmHg
Cognitive Preservation	RAAS inhibitors preferred	SBP <130 mmHg	MoCA, orthostatic vitals	Rapid titration in elderly

📚 Sources

Anderson CS, Heeley E, Huang Y, et al; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage (INTERACT-2). N Engl J Med. 2013;368(25):2355-2365. PMID: 23713578. [Source for: target SBP <140 within 1 hour in acute ICH; primary outcome (death or major disability) numerically lower (52.0% vs 55.6%, OR 0.87, p=0.06) but did not meet significance; secondary functional outcomes favored intensive arm.]
Qureshi AI, Palesch YY, Barsan WG, et al; ATACH-2 Investigators. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage (ATACH-2). N Engl J Med. 2016;375(11):1033-1043. PMID: 27276234. [Source for: target SBP 110-139 vs 140-179 in acute ICH — no significant difference in primary outcome (death or disability) but more renal adverse events in intensive arm. Tempers INTERACT-2 enthusiasm.]
PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-1041. PMID: 11589932. [Source for: secondary stroke prevention — perindopril+indapamide reduced stroke 28% (HR 0.72) and major vascular events 26%; foundational secondary-prevention BP-lowering evidence after stroke or TIA.]
Anderson CS, Huang Y, Lindley RI, et al; ENCHANTED Investigators. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet. 2019;393(10174):877-888. PMID: 30739745. [Source for: intensive BP lowering (target SBP 130-140) during/after IV thrombolysis did not improve functional outcome at 90 days but reduced symptomatic ICH (14.8% vs 18.7%, OR 0.75, p=0.0137).]
Sandset EC, Anderson CS, Bath PM, et al; ESO Guidelines Committee. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J. 2021;6(2):XLVIII-LXXXIX. PMID: 34780578. [Source for: ESO guideline on BP management in acute stroke — supports careful BP lowering in ICH, withholding aggressive lowering in acute ischemic stroke.]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115. PMID: 29133356. [Source for: post-stroke target <130/80 mmHg secondary prevention.]

🎯 Cerebrovascular Disease: Key Learning Points

🩸 Acute ICH Management

Selected mild-to-moderate ICH: target 140 mmHg and maintain 130–150
Avoid SBP <130 mmHg to prevent hypoperfusion
Use continuous infusion agents for precision
INTERACT-2 vs ATACH-2 evidence integration

🔧 Post-Endovascular Care

ENCHANTED2/MT found harm from a target <120 mmHg
Individualize BP with the stroke team; the trial did not test every target below 140
ENCHANTED-2/MT (Yang 2022) post-thrombectomy harm signal
Gradual transition to standard targets

🧠 Cognitive Preservation

Class 1 upgrade: SBP <130 mmHg for MCI prevention
SPRINT-MIND: 19% reduction in cognitive impairment
Midlife hypertension control crucial
Balance benefits vs falls risk in elderly

🧠 Cerebrovascular Disease